8-K: Turning Point Brands Soars on Q3, Boosts 2025 Outlook

Turning Point Brands reported strong third-quarter 2025 financial results, with consolidated net sales up 31.2% and a significant increase in Modern Oral product sales, leading to an upward revision of its full-year Adjusted EBITDA and Modern Oral sales guidance.

Summary

• Consolidated Net Sales for Q3 2025 increased 31.2% year-over-year to $119.0 million.
• Modern Oral Net Sales for Q3 2025 surged by 627.6% year-over-year to $36.7 million, representing 30.8% of total Company Net Sales.
• Adjusted EBITDA for Q3 2025 was $31.3 million, an increase of 17.2% over the prior year.
• Net Income increased 70.3% to $21.1 million, and Diluted EPS rose to $1.13 from $0.68 in the prior year.
• The Stokers segment saw net sales increase by 80.8% to $74.8 million, driven by Modern Oral, MST, and looseleaf growth.
• The Zig-Zag segment experienced a 10.5% decrease in net sales to $44.2 million, though it was up mid-single-digits sequentially excluding the Clipper business wind-down.
• The company raised its full-year 2025 Adjusted EBITDA guidance to $115.0 $120.0 million (from $110.0 $114.0 million).
• Full-year Modern Oral sales guidance was increased to $125.0 $130.0 million (from $100.0 $110.0 million).
• Turning Point Brands raised $97.5 million in net proceeds through an At the Market (ATM) offering program, with capital earmarked for high-return opportunities to accelerate Modern Oral growth.
• Total gross debt as of September 30, 2025, was $300.0 million, with net debt at $98.8 million and total liquidity of $267.8 million.

Sentiment

Score: 9

Explanation: The company reported exceptionally strong Q3 results, particularly in its high-growth Modern Oral segment, and significantly raised its full-year guidance for both Adjusted EBITDA and Modern Oral sales. This indicates strong operational performance and positive future outlook, despite a decline in the Zig-Zag segment.

Positives

• Consolidated Net Sales increased 31.2% year-over-year to $119.0 million.
• Modern Oral Net Sales grew by an exceptional 627.6% year-over-year to $36.7 million, now comprising 30.8% of total sales.
• Adjusted EBITDA increased 17.2% to $31.3 million.
• Gross Profit rose 39.7% to $70.4 million.
• Net Income increased 70.3% to $21.1 million.
• Diluted EPS improved to $1.13 from $0.68 in the prior year.
• Adjusted Diluted EPS increased to $1.27 from $0.91.
• Stokers segment Net Sales increased 80.8% to $74.8 million, with gross profit up 95.2% and gross margin expanding by 440 basis points to 60.2%.
• The company increased its full-year 2025 Adjusted EBITDA guidance to $115.0 $120.0 million.
• Full-year Modern Oral sales guidance was significantly increased to $125.0 $130.0 million.
• Successfully raised $97.5 million in net proceeds via an ATM offering to fund growth initiatives, particularly in Modern Oral.

Negatives

• Zig-Zag segment Net Sales decreased 10.5% from the prior year to $44.2 million.
• Consolidated selling, general and administrative (SG&A) expenses increased 50.5% from the prior year to $44.5 million, driven by Modern Oral-related sales and marketing investments and increased outbound freight costs.

Risks

• Forward-looking statements inherently involve risks and uncertainties, and actual events may differ materially from projections.
• New risks and uncertainties may emerge over time that the company cannot predict or identify.
• Preliminary financial estimates are subject to customary quarter-end closing and review procedures, and the final reported information in the Quarterly Report on Form 10-Q may differ materially.

Future Outlook

The company is optimistic about its future performance, increasing its full-year 2025 Adjusted EBITDA guidance to $115.0 $120.0 million and projected full-year 2025 Modern Oral sales to $125.0 $130.0 million. Management also anticipates qualifying its first U.S. white pouch production lines in the first half of 2026, signaling continued investment and expansion in the Modern Oral category.

Management Comments

• "Our consolidated third quarter results exceeded expectations."
• "Modern Oral sales were $36.7 million, increasing by 22% versus the prior quarter and 628% over the prior year."
• "In addition, we now expect to qualify our first U.S. white pouch production lines in the first half of 2026."

Industry Context

Turning Point Brands operates in the evolving consumer products sector, specifically focusing on alternative smoking accessories and consumables with active ingredients. The exceptional growth in Modern Oral sales highlights a significant market shift towards innovative, non-combustible nicotine products. This strong performance positions TPB favorably within a segment experiencing rapid expansion and consumer adoption, indicating successful adaptation to changing industry trends and consumer preferences.

Stakeholder Impact

• Shareholders are likely to benefit from the strong financial performance, increased earnings per share, and raised guidance, potentially leading to increased share value.
• Employees in the Modern Oral segment may see increased opportunities due to accelerated growth and investment.
• Customers can expect continued innovation and product availability, particularly in the Modern Oral category, as the company invests in production and marketing.

Next Steps

• Qualify the first U.S. white pouch production lines in the first half of 2026.
• Amend the At the Market (ATM) prospectus supplement and buyback authorization to provide for $200 million of capacity under each program.
• File the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, which will contain the full financial details.

Key Dates

Recommendation

Turning Point Brands delivered outstanding third-quarter results, significantly exceeding prior expectations and demonstrating robust growth, especially in the Modern Oral segment. The substantial increase in full-year guidance for both Adjusted EBITDA and Modern Oral sales signals strong underlying business momentum and management confidence. The strategic capital raise via the ATM program is well-positioned to fuel further expansion in high-return areas. While the Zig-Zag segment experienced a decline, the overall positive trajectory, strategic focus on growth categories, and improved profitability metrics make TPB a compelling 'strong buy' for investors seeking exposure to the evolving consumer products market.

Keywords

Turning Point Brands, TPB, Q3 2025, financial results, Modern Oral, Stokers, Zig-Zag, Adjusted EBITDA, net sales, consumer products, smoking accessories, consumables, alternative tobacco, earnings guidance